press-releases

 Oct 06, 2022, 08:30 ET  AHFIRM enrollment surpasses 200 of the planned 300 AH patients Enrollment completion now anticipated in Q2 2023 CUPERTINO, Calif., Oct. 6, 2022 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX), a biopharmaceutical company focused on developing epigenetic regulator programs for the treatment of acute organ injury and chronic liver diseases, today announced […]

 Sep 26, 2022, 08:30 ET  POSIMIR® is now commercially available in the U.S. for the treatment of post-surgical pain in adults following arthroscopic subacromial decompression surgery DURECT recently received an $8 million milestone payment for a new patent issuance and has now earned a $2 million milestone payment for first commercial sale of POSIMIR ATHLONE,

 Sep 06, 2022, 08:00 ET  CUPERTINO, Calif., Sept. 6, 2022 /PRNewswire/ — DURECT Corporation ( Nasdaq: DRRX) today announced that Dr. James E. Brown, President and CEO will be presenting virtually at the H.C. Wainwright 24th annual Global Investment Conference.  Presentation details are as follows: H.C. Wainwright Global Investment Conference Date:           

 Aug 04, 2022, 16:05 ET  –  Webcast of Earnings Call Today, August 4th at 4:30 p.m. ET –  Enrollment accelerating in the AHFIRM trial CUPERTINO, Calif., Aug. 4, 2022 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) today announced financial results for the three months ended June 30, 2022 and provided a corporate update. “We continue to

Jul 27, 2022, 16:15 ET CUPERTINO, Calif., July 27, 2022 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) today announced that it will report its second quarter 2022 financial results and host a conference call after the market close on Thursday, August 4, 2022. Thursday, August 4 @ 4:30pm Eastern Time / 1:30pm Pacific Time Toll Free: 1-877-869-3847

Jul 05, 2022, 08:30 ET CUPERTINO, Calif., July 5, 2022 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX), a biopharmaceutical company focused on epigenetic regulation to develop treatments for acute organ injury and chronic liver diseases, today announced the appointment of Timothy M. Papp as its Chief Financial Officer. In this new role, Mr. Papp will direct and oversee all financial